Four things to know from the proposed legislation:
1. One provision would remove the FDA’s “X waiver” from buprenorphine, meaning that pharmacists who are authorized to dispense controlled substances and have at least eight hours of training for treating and managing patients with substance use disorders could prescribe the opioid dependence therapy.
2. It directs HHS to identify incentives that would achieve increased domestic production of generic medicines and antibiotics.
3. The bill aims to “modernize” the FDA’s accelerated approval program, which includes requiring post-drug-approval studies before the treatment enters the market and simplifying the process of pulling a drug if drugmakers don’t conduct studies or if the drug fails to show a clinical benefit. Recent delays in the fast-track drug approval program have cost the U.S. about $18 billion.
4. To combat shortages of medical products during an emergency, another provision would require HHS to issue guidance on how the Strategic National Stockpile distributes its supplies.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.